Severe, refractory lupus successfully treated with engineered T cells derived from a healthy donor
nature.com/articles/s41...
nature.com/articles/s41...
Allogeneic CD19-targeting T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial - Nature Medicine
In a small trial of patients with severe systemic lupus erythematosus and nephritis, treatment with allogeneic T cells with a CD19 chimeric antigen receptor inserted into the T cell receptor locus and...
nature.com
August 27, 2025 at 3:06 PM
Severe, refractory lupus successfully treated with engineered T cells derived from a healthy donor
nature.com/articles/s41...
nature.com/articles/s41...
Engineered T cells (w/ CD19) is hitting it big for autoimmune diseases: single injection for 15 patients with 3 conditions--> all remissions, no need for immunosuppressive Rx
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
February 21, 2024 at 10:28 PM
Engineered T cells (w/ CD19) is hitting it big for autoimmune diseases: single injection for 15 patients with 3 conditions--> all remissions, no need for immunosuppressive Rx
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
We've already seen remarkable results for lupus and other autoimmune diseases with CD19 B cell depletion therapy. Now add IgG4 related disease (which has no treatment) in a new randomized trial
nejm.org/doi/full/10....
nejm.org/doi/full/10....
Inebilizumab for Treatment of IgG4-Related Disease | NEJM
IgG4-related disease is a multiorgan, relapsing, fibroinflammatory, immune-mediated
disorder with no approved therapy. Inebilizumab targets and depletes CD19+ B cells
and may be effective for treat...
nejm.org
November 14, 2024 at 3:15 PM
We've already seen remarkable results for lupus and other autoimmune diseases with CD19 B cell depletion therapy. Now add IgG4 related disease (which has no treatment) in a new randomized trial
nejm.org/doi/full/10....
nejm.org/doi/full/10....
Our treatments for refractory autoimmune disease keep getting more sophisticated with impressive outcomes.
Here is the first-in-human case of systemic sclerosis treated with engineered NK cells
www.cell.com/cell/fulltex...
Here is the first-in-human case of systemic sclerosis treated with engineered NK cells
www.cell.com/cell/fulltex...
An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis
This first-in-human use of an iPSC-derived CAR-NK therapy targeting CD19 and BCMA
demonstrates safe and marked clinical responses in a patient with severe refractory
systemic sclerosis, underscoring t...
www.cell.com
August 7, 2025 at 3:42 PM
Our treatments for refractory autoimmune disease keep getting more sophisticated with impressive outcomes.
Here is the first-in-human case of systemic sclerosis treated with engineered NK cells
www.cell.com/cell/fulltex...
Here is the first-in-human case of systemic sclerosis treated with engineered NK cells
www.cell.com/cell/fulltex...
Ooooh fascinating! Natural killer cells which are early responder so called innate cells could be reprogrammed to tackle severe autoimmune conditions akin to CAR-T cells in cancer #Immunosky 🧪
An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis
This first-in-human use of an iPSC-derived CAR-NK therapy targeting CD19 and BCMA
demonstrates safe and marked clinical responses in a patient with severe refractory
systemic sclerosis, underscoring t...
www.cell.com
July 7, 2025 at 6:56 PM
Ooooh fascinating! Natural killer cells which are early responder so called innate cells could be reprogrammed to tackle severe autoimmune conditions akin to CAR-T cells in cancer #Immunosky 🧪
New Year, new publication 💥🥳 B cell people, check out our report on the enhanced antibody responses in CD19-cre (and be aware of the issue if using this model in your conditional crossings)! rdcu.be/d5CqD
Enhanced antibody responses in CD19-Cre mice
Scientific Reports - Enhanced antibody responses in CD19-Cre mice
rdcu.be
January 9, 2025 at 8:04 AM
New Year, new publication 💥🥳 B cell people, check out our report on the enhanced antibody responses in CD19-cre (and be aware of the issue if using this model in your conditional crossings)! rdcu.be/d5CqD
Ca y est mes lymphocytes avec marqueurs cd19 sont enfin détectables aux analyses on peut donc commencer les premiers vaccins 🥳🥳🎉🎉🎊🎊
May 21, 2025 at 11:16 AM
Ca y est mes lymphocytes avec marqueurs cd19 sont enfin détectables aux analyses on peut donc commencer les premiers vaccins 🥳🥳🎉🎉🎊🎊
Review @jimmunol.bsky.social
Can autoimmune disease be cured by deep CD19+ cell depletion?
doi.org/10.1093/jimm...
Can autoimmune disease be cured by deep CD19+ cell depletion?
doi.org/10.1093/jimm...
March 21, 2025 at 5:58 PM
Review @jimmunol.bsky.social
Can autoimmune disease be cured by deep CD19+ cell depletion?
doi.org/10.1093/jimm...
Can autoimmune disease be cured by deep CD19+ cell depletion?
doi.org/10.1093/jimm...
Another major triumph for a refractory autoimmune disease—hemolytic anemia—through engineered T cells
@nejm.org
nejm.org/doi/full/10....
@nejm.org
nejm.org/doi/full/10....
CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia | NEJM
In patients with autoimmune hemolytic anemia (AIHA), the risk of relapse is high owing
to persistent autoreactive B-cell activity. Multirefractory AIHA is a more advanced
stage of disease that is d...
nejm.org
January 14, 2026 at 10:44 PM
Another major triumph for a refractory autoimmune disease—hemolytic anemia—through engineered T cells
@nejm.org
nejm.org/doi/full/10....
@nejm.org
nejm.org/doi/full/10....
Just a note of caution from someone who works in this field. We do not all agree that CD19 can distinguish long- from short-lived plasma cells. Here is just one of several studies showing it is not reliable as a marker.
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
Long-lived plasma cells in human bone marrow can be either CD19+ or CD19–
www.sciencedirect.com
October 11, 2024 at 12:12 AM
Just a note of caution from someone who works in this field. We do not all agree that CD19 can distinguish long- from short-lived plasma cells. Here is just one of several studies showing it is not reliable as a marker.
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
SARS-CoV-2 infection causes immunodeficiency in recovered patients by downregulating CD19 expression in B cells via enhancing B-cell metabolism www.nature.com/articles/s41...
Many thanks to bsky.app/profile/andr... for sharing this with me. COVID-19 destroys our immune system! Prevent reinfections!
Many thanks to bsky.app/profile/andr... for sharing this with me. COVID-19 destroys our immune system! Prevent reinfections!
SARS-CoV-2 infection causes immunodeficiency in recovered patients by downregulating CD19 expression in B cells via enhancing B-cell metabolism - Signal Transduction and Targeted Therapy
Signal Transduction and Targeted Therapy - SARS-CoV-2 infection causes immunodeficiency in recovered patients by downregulating CD19 expression in B cells via enhancing B-cell metabolism
www.nature.com
September 30, 2025 at 6:15 PM
SARS-CoV-2 infection causes immunodeficiency in recovered patients by downregulating CD19 expression in B cells via enhancing B-cell metabolism www.nature.com/articles/s41...
Many thanks to bsky.app/profile/andr... for sharing this with me. COVID-19 destroys our immune system! Prevent reinfections!
Many thanks to bsky.app/profile/andr... for sharing this with me. COVID-19 destroys our immune system! Prevent reinfections!
In a patient with treatment-resistant ulcerative colitis, CD19 CAR T-cell therapy led to drug-free remission and mucosal healing, suggesting that B-cell targeting may offer a novel therapeutic pathway. Read the full report: nej.md/48gcBZV
#MedSky #GastroSky
#MedSky #GastroSky
September 26, 2025 at 2:06 PM
In a patient with treatment-resistant ulcerative colitis, CD19 CAR T-cell therapy led to drug-free remission and mucosal healing, suggesting that B-cell targeting may offer a novel therapeutic pathway. Read the full report: nej.md/48gcBZV
#MedSky #GastroSky
#MedSky #GastroSky
Co-infusion of CD19-targeting and BCMA-targeting #CAR-T cells for treatment-refractory systemic #lupus erythematosus: a phase 1 trial @naturemedicine.bsky.social www.nature.com/articles/s41...
September 24, 2025 at 6:06 PM
Co-infusion of CD19-targeting and BCMA-targeting #CAR-T cells for treatment-refractory systemic #lupus erythematosus: a phase 1 trial @naturemedicine.bsky.social www.nature.com/articles/s41...
Preprint: Treatment of multiple sclerosis with CD19-targeting CAR-T-cells
www.researchsquare.com/article/rs-9...
www.researchsquare.com/article/rs-9...
March 19, 2026 at 2:09 AM
Preprint: Treatment of multiple sclerosis with CD19-targeting CAR-T-cells
www.researchsquare.com/article/rs-9...
www.researchsquare.com/article/rs-9...
COVID Acquired Immune Deficiency Syndrome (CAIDS)
www.nature.com/articles/s41...
www.nature.com/articles/s41...
SARS-CoV-2 infection causes immunodeficiency in recovered patients by downregulating CD19 expression in B cells via enhancing B-cell metabolism - Signal Transduction and Targeted Therapy
Signal Transduction and Targeted Therapy - SARS-CoV-2 infection causes immunodeficiency in recovered patients by downregulating CD19 expression in B cells via enhancing B-cell metabolism
www.nature.com
May 31, 2025 at 11:09 AM
COVID Acquired Immune Deficiency Syndrome (CAIDS)
www.nature.com/articles/s41...
www.nature.com/articles/s41...
January 15, 2026 at 2:09 AM
This is absolutely the most significant glycobiology paper so far this year. Increasing cell surface N-glycosylation makes viable allo CAR-T cells without deleting the endogenous TCR #glycotime
Glycan shielding enables TCR-sufficient allogeneic CAR-T therapy
SPPL3 deletion modifies glycosylation on primary T cells, reducing allogeneic immune
responses without impairing tumor control by anti-CD19 allogeneic CAR-T cells. SPPL3-null,
TCR-sufficient anti-CD19...
www.cell.com
August 31, 2025 at 8:41 PM
This is absolutely the most significant glycobiology paper so far this year. Increasing cell surface N-glycosylation makes viable allo CAR-T cells without deleting the endogenous TCR #glycotime
2) The treatment trial is led by Carmen Scheibenbogen and will be a follow-up study to the randomized Phase II trial of the CD19 antibody inebilizumab.
Tafasitamab also targets CD19 but is less expensive, so they want to test if this also works in a subgroup of 38 patients.
Tafasitamab also targets CD19 but is less expensive, so they want to test if this also works in a subgroup of 38 patients.
July 18, 2026 at 7:57 AM
2) The treatment trial is led by Carmen Scheibenbogen and will be a follow-up study to the randomized Phase II trial of the CD19 antibody inebilizumab.
Tafasitamab also targets CD19 but is less expensive, so they want to test if this also works in a subgroup of 38 patients.
Tafasitamab also targets CD19 but is less expensive, so they want to test if this also works in a subgroup of 38 patients.
sogenannte (BiTEs), die aus zwei unterschiedlichen monoklonalen Antikörpern zusammengesetzt sind und damit z. B. im Fall von Blinatumomab T-Zellen (über CD3) und Leukämiezellen (CD19 bei ALL) zusammenbringen und damit zur Zerstörung von Leukämiezellen führen
January 8, 2025 at 6:27 AM
sogenannte (BiTEs), die aus zwei unterschiedlichen monoklonalen Antikörpern zusammengesetzt sind und damit z. B. im Fall von Blinatumomab T-Zellen (über CD3) und Leukämiezellen (CD19 bei ALL) zusammenbringen und damit zur Zerstörung von Leukämiezellen führen
Great application of #radiopharmaceuticals for visualizing CD19+ CAR T cells in vivo.
www.science.org/doi/...
www.science.org/doi/...
November 24, 2024 at 2:18 PM
Great application of #radiopharmaceuticals for visualizing CD19+ CAR T cells in vivo.
www.science.org/doi/...
www.science.org/doi/...
RRIDs were included in this in Cell paper. We value the author's support of reproducibility. #BetterScience #reproducibility #ReproducibleResearch
mRNA-encoding CD19-targeting T cell engager for refractory immune thrombocytopenia
Read the full paper: mRNA-encoding CD19-targeting T cell engager for refractory immune thrombocytopenia
doi.org
September 25, 2026 at 7:00 AM
RRIDs were included in this in Cell paper. We value the author's support of reproducibility. #BetterScience #reproducibility #ReproducibleResearch